PPARα in the Epigenetic Driver Seat of NAFLD: New Therapeutic Opportunities for Epigenetic Drugs?

Nonalcoholic fatty liver disease (NAFLD) is a growing epidemic and the most common cause of chronic liver disease worldwide. It consists of a spectrum of liver disorders ranging from simple steatosis to NASH which predisposes patients to further fibrosis, cirrhosis and even hepatocarcinoma. Despite...

Descripción completa

Detalles Bibliográficos
Autores principales: Theys, Claudia, Lauwers, Dorien, Perez-Novo, Claudina, Vanden Berghe, Wim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775974/
https://www.ncbi.nlm.nih.gov/pubmed/36551797
http://dx.doi.org/10.3390/biomedicines10123041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775974/
https://www.ncbi.nlm.nih.gov/pubmed/36551797
http://dx.doi.org/10.3390/biomedicines10123041

Ejemplares similares